Analyst Price Target Update on Catalent (NYSE:CTLT)

Catalent (NYSE:CTLT): The mean short term price target for Catalent (NYSE:CTLT) has been established at $27.9 per share. The higher price target estimate is at $31 and the lower price target estimate is expected at $25 according to 5 Analyst. The stock price is expected to vary based on the estimate which is suggested by the standard deviation value of $2.41

Many analysts have stated their opinion on the company shares. Major Brokerage house, William Blair downgrades its ratings on Catalent (NYSE:CTLT). According to the latest information available, the shares are now rated Market Perform by the analysts at the agency. Previously, the analysts had a Outperform rating on the shares. The rating by the firm was issued on May 5, 2016. Company shares have received an average consensus rating of Hold for the current week

On the companys insider trading activities, The Securities and Exchange Commission has divulged that Walsh Matthew M, officer (See Remarks) of Catalent, Inc., had unloaded 21,197 shares at an average price of $28.85 in a transaction dated on May 27, 2016. The total value of the transaction was worth $611,533.

Catalent (NYSE:CTLT) stock ended Monday session in the red zone in a volatile trading. The stock closed down 0.34 points or 1.48% at $22.57 with 1,478,691 shares getting traded. Post opening the session at $22.95, the shares hit an intraday low of $22.48 and an intraday high of $23.43 and the price was in this range throughout the day. The company has a market cap of $2,814 million and the number of outstanding shares have been calculated to be 124,659,595 shares. The 52-week high of Catalent (NYSE:CTLT) is $34.415 and the 52-week low is $18.92.

Catalent, Inc. is a provider of advanced delivery technologies and development solutions for drugs, biologics and consumer health products. The Companys segments include Oral Technologies, Medication Delivery Solutions, and Development and Clinical Services. The Oral Technologies segment provides advanced oral delivery technologies, including formulation, development and manufacturing of oral dose forms for prescription and consumer health products across all phases of a molecules lifecycle. The Medication Delivery Solutions segment provides formulation, development and manufacturing services for delivery of drugs and biologics, administered through injection, inhalation and ophthalmic routes, using both traditional and advanced technologies. The Development and Clinical Services segment provides manufacturing, packaging, storage and inventory management for drugs and biologics in clinical trials.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *